STAT3 and renal cell adenocarcinoma: The results of our study also demonstrate the need for future clinical studies of therapies investigating blockage of gp130 pathways, i.e., bazedoxifene, which blocks p-STAT3 inhibitor [39], and also combined with other blockers like VEGF-TKIs [40] to prolong survival in patients with RCC [41].